Navigation Links
University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia
Date:10/1/2008

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that it has shipped its non-invasive WavSTAT(R) Optical Biopsy System to the University of Southern California to demonstrate the clinical value of the Optical Biopsy System as an adjunctive tool to improve clinical sensitivity in identifying dysplasia or cancer in the esophagus. This marks the final phase of a study which has been conducted over the past three years.

Earlier this month, SpectraScience announced that it had delivered WavSTAT Systems to the Mayo Clinic and San Diego VA Hospital for similar studies. Other participants in the study include Minnesota Gastroenterology, P.A. and the Boston University VA Hospital.

Jim Hitchin, CEO of SpectraScience, commented, "We are pleased to be moving forward with our clinical study to demonstrate the value of the WavSTAT System in screening for esophageal cancers and pre-cancers, and believe that the System can be instrumental in helping doctors more reliably and efficiently detect pre-cancerous tissue at sufficiently early stages to provide more effective treatment."

WavSTAT Overview

The WavSTAT Optical Biopsy System was approved by the FDA in November of 2000 as safe and effective for adjunctive use during endoscopy of the colon to improve a physician's sensitivity to identify pre-cancerous polyps. The System also received the CE Mark in Europe in September 2007. The approved WavSTAT System uses a low power, non-significant risk laser to scan tissue and instantaneously help the physician determine whether small polyps are normal or pre-cancerous without physically removing the tissue. If polyps are determined to be pre-cancerous, they can be removed during the same procedure.

Current standards of care dictate that if a patient has severe chronic symptoms of heartburn, an endoscopy of the esophagus may be warranted and, if indicated, multiple physical biopsies are taken to check for pathology of dysplasia or cancer. During endoscopic examination, diseased tissue is not always visually apparent, especially at the pre-malignant stages. As a result, physicians take physical biopsies at visually suspicious areas, oftentimes randomly, in an effort to find diseased tissue.

The clinical use of the WavSTAT System to improve the endoscopist's clinical sensitivity in identifying dysplasia or cancer in the esophagus will be evaluated. The hypothesis that the sensitivity of a WavSTAT-assisted endoscopic examination improves that of standard endoscopy alone will be tested. If this hypothesis is correct, the physician should be able to take fewer physical biopsies, decrease the duration of the exam and minimize discomfort of the patient.

Background

Acid reflux, or heartburn, is a common ailment experienced by almost all adults at some point in their lives. As many as 44% of adults in the United States report having heartburn at least once a month; 14% report having it weekly and 7% experience it daily. If heartburn occurs often, or other symptoms such as difficulty swallowing or weight loss develop, a diagnosis of gastro-esophageal reflux disease (GERD) is considered. It is reported that approximately 50 million Americans have GERD symptoms. In most cases, GERD is benign, however, when GERD symptoms are frequent or chronic, a patient should be considered as a candidate to receive an endoscopy of the esophagus.

Barrett's esophagus is a disease of the lower esophagus thought to be caused primarily by GERD. Approximately 10-20% of GERD patients are believed to have Barrett's esophagus. In Barrett's, the lining of the esophagus changes to a type of tissue similar to that sometimes found in the small intestine called intestinal metaplasia. Currently, Barrett's can only be confirmed by examination of tissue biopsies obtained during an endoscopy of the esophagus.

Because the diagnosis of dysplasia has such a crucial impact on disease management and subsequent patient outcomes, a system that can aid in differentiating between suspect esophageal tissue with dysplasia or without dysplasia in real-time would have great clinical utility.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) Cervical Imaging System has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods currently available.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x 201

Hayden Communications

Investor Relations

Todd Pitcher

(858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
2. University of Pennsylvania scientists move optical computing closer to reality
3. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
4. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
5. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
6. CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
7. Most developing countries ill-equipped to ensure global biosafety: UN University
8. Nanocopoeia Licenses New Polymer-Based Biomaterials Platform From the University of Western Ontario
9. University of Pennsylvania engineers reveal what makes diamonds slippery at the nanoscale
10. Court Determines that University of Pittsburgh and Artecel Have Sole Rights to Adipose-Derived Stem Cell Patent
11. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):